UroGen Pharma
URGN
80 hedge funds and large institutions have $287M invested in UroGen Pharma in 2020 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 27 increasing their positions, 31 reducing their positions, and 7 closing their positions.
1.33% more ownership
Funds ownership: 66.88% → 68.21% (+1.3%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
5% less funds holding
Funds holding: 84 → 80 (-4)
13% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 31
25% less capital invested
Capital invested by funds: $382M → $287M (-$95M)
25% less call options, than puts
Call options by funds: $3.72M | Put options by funds: $4.96M
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WCM
Wildcat Capital Management
New York
|
+$7.97M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$4.55M |
| 3 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$2.25M |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$2.04M |
| 5 |
VOYA Investment Management
Atlanta,
Georgia
|
+$2.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.8M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
-$2.19M |
| 3 |
Morgan Stanley
New York
|
-$1.98M |
| 4 |
SG Americas Securities
New York
|
-$1.58M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.1M |
URGN Hedge Fund Activity: Q3 2020 in Review
80 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q3 2020, worth a combined $287M — down 25% from $382M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of URGN and 3 opened new positions — a net loss of 4 holders — while 31 trimmed existing stakes and 27 added.
The largest buyer was Wildcat Capital Management, adding an estimated $7.97M. The largest seller was Fidelity Investments, cutting an estimated $3.8M.
- 80 institutional investors held UroGen Pharma (URGN) as of Q3 2020, down from 84 in Q2 2020.
- Funds reported $287M of UroGen Pharma stock for Q3 2020, down 25% quarter-over-quarter.
- 3 funds opened new UroGen Pharma positions in Q3 2020 and 7 closed out, a net change of -4 holders.
- The largest UroGen Pharma buyer in Q3 2020 was Wildcat Capital Management, an estimated $7.97M added.
- The largest UroGen Pharma seller in Q3 2020 was Fidelity Investments, an estimated $3.8M sold.
Based on aggregated 13F filings for Q3 2020.